Loading
Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer.
Jong-Mu Sun is a medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Lancet report of KEYNOTE-590, which showed that pembrolizumab plus cisplatin and fluorouracil improved overall survival compared with chemotherapy alone in untreated advanced oesophageal cancer, the basis for pembrolizumab's approval in this setting. He also runs thoracic oncology trials.
| Title | Journal | Year |
|---|---|---|
| KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer | The Lancet | 2021 |
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tags oesophageal, trialist.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tags oesophageal, trialist.
Shares KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer, Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tags oesophageal, trialist.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares the tags immunotherapy, trialist.